Krishna Institute of Medical Sciences Limited

rs,

nager, Department of Corporate Services Bombay Stock Exchange Ltd (BSE) Phiroze Jheejheebhoy Towers, Dalal Street, Mumbai - 400 001. Scrip Code - 543308 ISIN: INE967H01025 Dear Sir, Sub: Investo

Rs. 45,000

entre” in Hyderabad with 50 beds and performed heart surgeries at an unimaginable low cost of just Rs. 45,000 only. Dr. Rao never turned away any patient from the hospital for want of money. The brand “Krishna

rs 6

h as Financial counseling tool which uses AI to help patients with surgery costings among many others 6 Private & Confidential Board of Directors Dr. Bhaskara Rao Bollineni Chairman & Managing Director

7.0%

Director 7 Private & Confidential Shareholding Pattern - As on 31st March, 2025 Retail Pre IPO, 7.0% Retail & Others, 4.6% Promoter & Promoter Group, 38.8% Share Holder Promoter SBI MF HD

4.6%

onfidential Shareholding Pattern - As on 31st March, 2025 Retail Pre IPO, 7.0% Retail & Others, 4.6% Promoter & Promoter Group, 38.8% Share Holder Promoter SBI MF HDFC MF AXIS MF SBI

38.8%

As on 31st March, 2025 Retail Pre IPO, 7.0% Retail & Others, 4.6% Promoter & Promoter Group, 38.8% Share Holder Promoter SBI MF HDFC MF AXIS MF SBI Insurance Nomura Kotak Fund

17.2%

7,040 78,50,000 Amansa Holdings Private Limited 77,04,880 NIPPON MF 61,88,044 FII, 17.2% DII, 32.4% No of Shares Share Holding % Category 15,52,56,520 38.8% 6.3% 4.8% 4.5% 3.5%

32.4%

50,000 Amansa Holdings Private Limited 77,04,880 NIPPON MF 61,88,044 FII, 17.2% DII, 32.4% No of Shares Share Holding % Category 15,52,56,520 38.8% 6.3% 4.8% 4.5% 3.5% 2.9% 2.5%

6.3%

61,88,044 FII, 17.2% DII, 32.4% No of Shares Share Holding % Category 15,52,56,520 38.8% 6.3% 4.8% 4.5% 3.5% 2.9% 2.5% 2.4% 2.0% 1.9% 1.5% DII DII DII DII DII DII F

4.8%

,044 FII, 17.2% DII, 32.4% No of Shares Share Holding % Category 15,52,56,520 38.8% 6.3% 4.8% 4.5% 3.5% 2.9% 2.5% 2.4% 2.0% 1.9% 1.5% DII DII DII DII DII DII FII

4.5%

FII, 17.2% DII, 32.4% No of Shares Share Holding % Category 15,52,56,520 38.8% 6.3% 4.8% 4.5% 3.5% 2.9% 2.5% 2.4% 2.0% 1.9% 1.5% DII DII DII DII DII DII FII DII

3.5%

17.2% DII, 32.4% No of Shares Share Holding % Category 15,52,56,520 38.8% 6.3% 4.8% 4.5% 3.5% 2.9% 2.5% 2.4% 2.0% 1.9% 1.5% DII DII DII DII DII DII FII DII FII

“• The procedure is performed through the urethra with no incisions, under real-time MRI guidance for maximum accuracy and safety.”

“• This technology uses focused beams of radiation to precisely target abnormal tissue in the brain, helping preserve surrounding healthy areas.”

“• With this addition, we aim to expand treatment options and provide access to advanced, minimally invasive neurosurgical care.”

“Best Super-Specialty Hospital in Telangana National Quality Excellence Awards 2020 Only Hospital in Telangana to get NABH Accredition for Emergency Department 2021 Ranked No.1 in Hyderabad for Cardiology, Neurosciences, Nephrology & Emergency Times Health Survey Times of India 13 Private & ConfidentialINTERNATIONAL ACCREDITATION Consistent Performer over 2 decades (Rupees in Millions) 30,670 7,590 25,143 22,235 CAGR: 26.9% 11,287 16,711 6,200 5,766 CAGR: 29.7% 5,217 2,412 263 2005 No.”

“• PAT at INR 106 Cr in Q4 FY25 against INR 72 Cr and INR 93 Cr in Q4 FY24 and Q3 FY25 respectively.”

“• Consolidated EPS for FY25 of INR 9.6, a growth of 24.0% on YoY basis.”

“• Consolidated Key Financials figures are as follows (Rs in Cr) : Particulars Total Income Less : Other Income Revenue from Operations PBT* Add : Interest Add : Depreciation Less : Gain on fair valuation of Call option/Share of loss from associate Consoldiated - FY25 Q4 Results Q4 FY25 Q3 FY25 Q4 FY24 QoQ YoY 801.4 4.5 796.9 134.0 26.7 52.6 10.8 790.2 17.8 772.4 134.6 25.7 44.7 637.6 3.8 633.8 100.0 16.4 46.3 -0.1 1.4% 25.7% 3.2% -0.4% 25.7% 34.0% Reported EBITDA (Incl.”

“Capex 350-400 Cr 180-200 Cr 500-525 Cr 70-75 Cr 40-50 Cr Cancer Centre / Mother & Child 90-110 Cr All Specialities All Specialities 300-350 Cr 300-350 Cr Revised Expected Year of Operation Q2 FY26 Q2 FY26 Q1 FY26 Q1 FY26 Q2 FY26 Q4 FY26 Q1 FY27 Q4 FY27 28 Private & Confidential KIMS UAIMS Hospital, Sangli About Sangli: Sangli is known as the sugar bowl of India due to its high sugarcane productivity.”

VISION

1

OUR MISSION

1

Operational Parameter

1

VISION

To be the most preferred healthcare services brand by providing affordable care and best clinical outcomes to patients. And to be the best place to work for doctors and employees.

OUR MISSION

Provide affordable quality care to our patients with patient-centric systems and processes. Enable clinical outcome-driven excellence by engaging modern medical technology. Provide a strong impetus for doctors to pursue academics and medical research. S T N ATIE P Most Preferred Healthcare Provider DOCTORS EMPLOYEES INVESTO RS Affordable Quality Care Best-in-Class Facilities Patient Centric Systems & Processes Clinical Outcome Driven Excellence Latest Medical Technology Strong Academics & Research Oriented Enriching Atmosphere Collaborative Culture Growth Driven Career Approach Transparent Governance Strong Operational Performance Consistent Growth 2 Private & Confidential Multi Specialty Care Brain • Neurology • Neurosurgery • Psychiatry • Neuro Rehabilitation Heart • Cardiology • Cardiac Surgery • Vascular Surgery • Heart Transplant • Cardio Rehabilitation Lung • Pulmonology • Interventional Pulmonology • Thoracic surgery • Lung Transplant ENT • Ear • Nose • Throat • Head and Neck Su

Operational Parameter

ARPOB: 18,000 Key Existing Specialities: Urology, Orthopaedics, CVTS, Neurosurgery, Internal Medicine & Critical Care, Cardiology, Gastroenterology, Nephrology & Kidney Transplant Surgery, Emergency Medicine Proposed Specialities to be added - Joint Replacement Surgery, Neurology, Neuro & Spine Surgery, Pulmonology, Surgical Gastroenterology, Liver Transplant 29 Private & Confidential Profit and Loss Statement (Rupees in Millions) Particulars Consolidated Q4 FY25 Q3 FY25 Q4 FY24 QoQ(%) YoY(%) FY25 FY24 YoY(%) Operating Revenue 7,969 7,724 6,338 3.2% 25.7% 30,351 24,982 Other Income Total Revenue** EBITDA** 45 8,014 2,025 178 7,902 2,050 38 -74.7% 18.4% 319 161 6,376 1,628 1.4% -1.2% 25.7% 30,670 25,143 24.4% 8,148 6,533 21.5% 98.1% 22.0% 24.7% EBITDA (%) on total revenue 25.3% 25.9% 25.5% 26.6% 26.0% PBT* 1,340 1,346 1,000 -0.4% 34.0% 5,581 4,595 21.5% PBT (%) on total revenue 16.7% 17.0% 15.7% 18.2% 18.3% PAT* 1,061 925 715 14.7% 48.4% 4,148 3,359 23.5% PAT (%) on total revenue 13.2%